X0306 4/A 2017-08-31 2017-08-03 0 0000891293 CTI BIOPHARMA CORP ctic 0001276750 KIRSKE DAVID C/O CTI BIOPHARMA CORP. 3101 WESTERN AVE., SUITE 600 SEATTLE WA 98121 0 1 0 0 EVP, Chief Financial Officer Non-Qualified Stock Option (right to buy) 3.25 2017-08-31 4 A 0 25000 0 A 2027-08-31 Common Stock 25000 25000 D On August 3, 2017, the reporting person filed a Form 4 which inadvertently reported that, on August 1, 2017 (the first day of the reporting person's employment with CTIC), CTIC granted the reporting person an option to purchase 25,000 shares of CTIC Common Stock. In fact, as reported in this amendment, such stock option was not granted until August 31, 2017 (the last day of the month in which the reporting person was first employed by CTIC). The stock options will vest over a period of one year from the grant date in twelve equal monthly installments. The grant will accelerate and fully vest should Mr. Kirske's employment be terminated by the Company without cause within the first six months after the grant date. By: Bruce Seeley, Attorney-in-fact For: David Kirske 2017-10-19